This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent. Top assignee: Prophylix Pharma as. Active years: 2014.
Company Filing History:
Years Active: 2014
Title: Mette Kjaer Killie: Innovator in Neonatal Health
Mette Kjaer Killie is a notable inventor based in Tromso, Norway. She has made significant contributions to the field of neonatal health, particularly in the prevention of neonatal alloimmune thrombocytopenia (NAIT). Her innovative approach has the potential to improve outcomes for mothers and their newborns.
Latest Patents
Mette Kjaer Killie holds a patent for a preparation useful for, and a method for the treatment of neonatal alloimmune thrombocytopenia (NAIT). This patent describes a preparation that can be administered to women post-childbirth to avoid immunization and antibody production, which could lead to NAIT and fetal/neonatal bleeding in subsequent pregnancies. The method involves administering a preparation containing antibodies to HPA1a within 72 hours after delivery in the first non-compatible pregnancy.
Career Highlights
Throughout her career, Mette Kjaer Killie has worked with Prophylix Pharma, where she has contributed her expertise in neonatal health. Her work has been instrumental in advancing the understanding and treatment of conditions affecting newborns.
Collaborations
Mette Kjaer Killie has collaborated with notable professionals in her field, including Bjorn Ragnar Skogen and Anne Husse-Bekk. These collaborations have further enriched her research and innovations.
Conclusion
Mette Kjaer Killie's contributions to neonatal health through her patent and career achievements highlight her as a significant figure in the field. Her work continues to pave the way for improved health outcomes for mothers and their infants.